The heart fail­ure mar­ket gets a lit­tle more crowd­ed, as Eli Lil­ly and Boehringer In­gel­heim score a win for Jar­diance

Watch out, Farx­i­ga: There’s an­oth­er SGLT2 in­hibitor ap­proved to treat heart fail­ure pa­tients with re­duced ejec­tion frac­tion (HFrEF).

On Wednes­day, Eli Lil­ly and Boehringer In­gel­heim …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER